Germany is the largest medical cannabis import market in the world, and Canadian Licensed Producers already hold the dominant position. In the first quarter of 2026 alone, Canada supplied 26,753 kg out of 50,539 kg total imports, representing 53% of everything entering the German pharmacy system. That leadership is not guaranteed, and competition is intensifying as Portugal, Denmark, and emerging suppliers from Colombia and Australia gain footholds.
If you are a Canadian LP with export authorisation under the Cannabis Act and you are not yet active in the German market, the window to establish a durable position is open now. Here is what you need to know to enter or strengthen your presence.
The German medical cannabis market rewards producers who can demonstrate consistent quality, full regulatory compliance, and supply chain reliability across repeated batch deliveries. Canadian LPs hold a structural advantage in that position, but the window for new entrants is narrowing as major producers formalise their distribution relationships.
Producers who invest in EU-GMP pathway planning now, build import partnerships through direct commercial negotiation, and position their product quality documentation to meet European pharmacy standards will be best placed to capture the next phase of Germany's rapid import growth.
To explore how AlphaLeaf's premium indoor flower can support your procurement requirements or supply chain strategy, contact our team through the international page or visit our about us page to learn more about our facility and certifications.
Why Germany is the priority market for Canadian exporters
Germany imported 201,094 kg of cannabis in 2025, more than doubling 2024's volume of 72,850 kg. Projections for 2026 point to roughly 250,000 kg. That is a market growing faster than any other regulated jurisdiction globally, driven by the February 2024 Medical Cannabis Act (MedCanG), which expanded pharmacy access, online consultations, and mail delivery to patients.
For Canadian producers, the economics are compelling. Exports are not subject to Canada's $1-per-gram excise tax, which domestic sales carry. International margins are meaningfully higher, and Germany's pharmacy-based distribution model rewards consistent quality over time rather than the promotional churn of retail cannabis. A relationship with a licensed German importer or wholesaler can become a recurring, high-volume offtake arrangement.
The EU-GMP requirement: the non-negotiable starting point
Under the MedCanG, all cannabis imported into Germany must be produced in an EU-GMP-certified facility or processed through one before entering the country. This is the single most common barrier for Canadian LPs entering the European market.
There are two paths to address this:
- Obtain EU-GMP certification for your Canadian facility. This is a multi-year process involving a site audit by a European regulatory authority. It is the preferred long-term path for LPs with significant export volume.
- Partner with an EU-GMP-certified processing hub. Many Canadian exporters route their product through licensed processors in Portugal, which serves as Europe's primary tolling hub due to its proximity to Germany and established regulatory relationships. Denmark also increasingly serves this role. The product is received, quality-tested, and repackaged under EU-GMP conditions before distribution to German wholesalers.
Health Canada's export authorisation framework under Part 14 of the Cannabis Regulations permits licensed producers holding a standard cultivation licence to export dried flower for medical or scientific purposes with the appropriate permits. The receiving country must permit the import, and German importers are required to hold a Betäubungsmittel (BtM) import licence issued by BfArM, Germany's Federal Institute for Drugs and Medical Devices.
What German importers look for in a Canadian supplier
A procurement manager at a German cannabis wholesaler or pharmacy chain will open your batch Certificate of Analysis (COA) before anything else. The German market has very specific expectations. Here is what distinguishes competitive product:
- Consistent cannabinoid potency. Products with THC in the 20-30%+ range are in strong demand for higher-severity patient indications. Batch-to-batch consistency is critical, as buyers are building patient protocols around specific products.
- Clean microbial and contamination profile. EU pharmacopoeial limits for total aerobic count, yeast and mould, and heavy metals are stricter than Canadian baseline requirements. ISO-certified lab testing against these benchmarks is a prerequisite, not a differentiator.
- Full batch traceability documentation. German importers require chain-of-custody documentation from seed or cutting through to final packaging. Any gap in the trace record raises compliance flags during their own BfArM regulatory submissions.
- Large-format, premium flower. The German pharmacy system serves patients, not recreational consumers. Presentation matters. Large-bud, hand-trimmed flower signals quality to both the importer and the dispensing pharmacist. Machine-trimmed or small-bud product faces significant pricing pressure.
AlphaLeaf's Ice Cream Cake (30.3% THC) and other cultivars from our Montreal indoor facility are produced to precisely these standards: hand-trimmed, large-bud format, ISO-certified testing, and full batch traceability through our Montreal facility. Our production is built around the B2B export buyer's requirements, not the domestic retail shelf.
Export permits, legislative updates, and finding your German partner
Under the Cannabis Act and associated regulations, each export shipment requires a permit. The process includes:
- Confirming the importing country's legal framework and obtaining a corresponding import permit from BfArM or the German importer's authorising body.
- Submitting an export permit application to Health Canada's Office of Controlled Substances, including details on the consignee, product, quantity, and shipment route.
- Ensuring all shipping documentation (phytosanitary certificate where required, commercial invoice, COA, and certificate of origin) accompanies the shipment.
- Complying with the Single Convention on Narcotic Drugs reporting requirements, as cannabis remains a Schedule I substance under international treaty.
Processing times for export permits vary, and LPs with active export programmes typically apply for blanket annual permits for established trade relationships rather than transaction-by-transaction permits. Working with a customs broker experienced in Health Canada narcotics exports is strongly recommended.
Legislative developments to monitor
Canadian exporters should be tracking proposed amendments to Germany's Medical Cannabis Act that have moved through the Bundestag since late 2025. The Federal Cabinet approved a draft bill on October 8, 2025, that would restrict telemedicine prescriptions and eliminate mail-order pharmacy delivery. These changes would reduce patient access pathways without eliminating the underlying prescription-based market.
The net effect on import volumes is expected to be modest for established suppliers with strong pharmacy relationships. However, LPs entering the market now should build distribution relationships that prioritise bricks-and-mortar pharmacy networks over mail-order channels, which carry more regulatory risk in the near term.
Finding the right German import partner
Canadian LPs typically do not sell directly to German pharmacies. The operating model involves a licensed German importer or wholesaler who holds the BtM licence, manages BfArM compliance, and distributes into the pharmacy network. Several Canadian companies have formalised these relationships through equity stakes: Organigram recently closed its acquisition of Sanity Group, and High Tide took a 51% stake in Remexian Pharma.
For LPs without the capital for acquisition, commercial supply agreements with established German importers are the standard entry point. These agreements typically specify:
- Minimum annual volumes and delivery scheduling
- Quality specifications (potency range, contamination limits, trim standard)
- COA requirements (ISO-accredited lab, specific testing panels)
- Pricing mechanism (often tied to BfArM's established pricing bands or negotiated on a per-batch basis)
- EU-GMP compliance responsibility (which party manages the tolling arrangement)
If you are approaching the German market for the first time, engaging a European cannabis trade consultant or attending B2B forums such as Spannabis or the Cannabis Europa conference is a practical way to connect with vetted import partners. AlphaLeaf maintains active relationships with international partners and welcomes discussions with importers evaluating new Canadian suppliers. You can reach our international sales team through the international enquiries page.
Frequently Asked Questions
Does AlphaLeaf export cannabis to Germany?
AlphaLeaf holds export authorisation under the Cannabis Act and produces premium dried flower meeting the quality standards required by European importers, including ISO-certified testing and full batch traceability. We welcome enquiries from German importers and licensed wholesalers through our contact page.
What EU-GMP certification do Canadian cannabis exporters need?
All cannabis entering Germany for medical use must originate from or be processed through an EU-GMP-certified facility. Canadian LPs either pursue EU-GMP certification for their own facility or engage a licensed tolling partner in a country like Portugal or Denmark to process product before German market entry.
How much cannabis does Germany import from Canada?
Canada was the largest single supplier of medical cannabis to Germany in 2025, exporting 93,006 kg and representing nearly half of Germany's total annual imports of 201,094 kg. In Q1 2026, Canada supplied 26,753 kg, or 53% of Germany's quarterly import total of 50,539 kg.
What are the main quality requirements for medical cannabis sold in Germany?
German pharmacy-grade cannabis must meet EU pharmacopoeial limits for microbial contamination and heavy metals, carry a full COA from an ISO-accredited laboratory, and be accompanied by complete chain-of-custody documentation. Large-bud, hand-trimmed flower commands premium pricing in the pharmacy supply chain.
Can Canadian LPs sell directly to German pharmacies?
Generally, no. German pharmacies source from licensed importers and wholesalers holding BtM licences issued by BfArM. Canadian LPs establish supply relationships with these intermediaries, who manage the regulatory compliance requirements on the German side of the transaction.
